The Bull Rankings scorecard — our quality-growth score is 87.2 / 100, built from three pillars scored 0–100: Quality 80, Growth 96, Value 86 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 7% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Neurocrine Biosciences sits at the intersection of high‑margin specialty drugs and a pipeline that keeps its revenue engine turning. The Bull Rankings model gives it a quality‑growth score of 87.2/100, with Growth at 96 and Quality at 80. That 96 on Growth is the engine that justifies the current price of $142.44. The company’s profit margin of 20.9 % and ROE of 19.1 % confirm that the business is not just growing; it is turning cash efficiently. Even with a P/E of 20.9—below the Healthcare median—the stock is still trading on a PEG of 0.28, signaling that the market expects continued expansion. In short, the strongest pillar—Growth—drives the thesis, while the modest Quality score merely indicates a solid, but not spectacular, operating base.
What the business actually is
Neurocrine’s revenue stream is anchored in a handful of niche indications. INGREZZA treats tardive dyskinesia and chorea linked to Huntington’s disease, while Orilissa and Oriahnn address endometriosis and uterine fibroids, respectively. CRESENTITY tackles congenital adrenal hyperplasia, and the company also markets ALKINDI and Efmody. These products serve neurologic, psychiatric, endocrine, and immunologic markets—segments where patient populations are relatively stable and competition is limited. The pipeline—NBI‑1076986 for movement disorders, Osavampator for major depressive disorder, and NBI‑1117568 for…—adds a growth layer that keeps the revenue engine primed.
Why it can (or can't) keep compounding
The durability case hinges on two facts. First, the company’s free‑cash‑flow of $870 million in the trailing twelve months shows it can fund growth without external capital. Second, the low debt‑to‑equity of 0.12 and beta of 0.4 imply a stable capital structure and low volatility. The Durable high returns signal from the model confirms that the business can sustain its margins; the Profit margin of 20.9 % is a moat that competitors find hard to erode because of the specialized nature of the indications. A new entrant would need to replicate years of clinical data and regulatory approvals—an expensive, slow process that preserves Neurocrine’s lead.
The valuation question
The P/E of 20.9 sits below the Healthcare median, so the price is not paying a premium for earnings. However, the reverse‑DCF tells a different story: it assumes a free‑cash‑flow growth of 7 % in year 1, tapering to 4 % by year 10. This starting rate is lower than the trailing revenue growth of 34.4 %. In plain terms, the market is already pricing in a slowdown from the recent surge. The analyst consensus of $207.29 and a target range of $164–$253 suggest that some investors still see upside, but the current price already discounts the most aggressive growth trajectory.
The bear case
The softest pillar—Quality at 80—does not signal weakness, but it does leave room for concern. A 20.9 % profit margin is solid, yet the company’s debt‑to‑equity of 0.12 is low, meaning it has little room to absorb a sudden cash‑flow shock. If the free‑cash‑flow growth were to dip below the 7 % implied by the reverse‑DCF, the valuation would collapse. The Diluting shareholders signal warns that ongoing share issuances could erode earnings per share, tightening the margin further.
What would change our mind
- Revenue growth falling below 20 % for two consecutive quarters would undermine the 96 Growth score and push the reverse‑DCF growth assumption higher than reality.
- Profit margin slipping below 15 % would erode the 20.9 % figure that underpins the company’s cash‑flow generation.
- Debt‑to‑equity rising above 0.25 would signal a shift toward leverage, increasing financial risk and potentially triggering the Diluting shareholders warning.
If any of these thresholds were breached, the model’s 87.2/100 score would deteriorate, and the current price would appear overvalued.